Immunomodulation in stem-cell transplantation

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 452-457

  Abo Zena, Reem A ^a   Horwitz, Mitchell E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHOXSALEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOTOSENSITIZING AGENT; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOLOGICAL ADJUVANT;

ALLOGRAFT; ARTICLE; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; EXPERIENCE; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HIRSUTISM; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; KIDNEY BLOOD FLOW; MICROANGIOPATHY; PRIORITY JOURNAL; PUBLICATION; SIDE EFFECT; STEM CELL TRANSPLANTATION; ANIMAL; IMMUNOLOGY; METHODOLOGY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; GRAFT VS HOST DISEASE; HUMANS; STEM CELL TRANSPLANTATION;

EID: 0036667396     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00174-1     Document Type: Review

References (45)

1. Bone marrow transplantation
2. Immunosuppressive strategies in transplantation
3. Non-myeloablative stem cell transplants
4. Acute graft-vs-host disease: Pathobiology and management
5. New therapeutic modalities in the treatment of graft-versus-host disease
6. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute-graft-versus-host disease after marrow transplantation for leukemia
7. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods
8. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
9. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation
10. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis?
11. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation
12. Mycophenolate mofetil
13. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation
14. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin
15. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: Four years of experience
16. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
17. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
18. Sirolimus, a new, potent immunosuppressive agent
19. Campath-1H monoclonal antibody therapy
20. In vivo CAMPATH-1H prevents graft-versus-host-disease following non-myeloablative stem cell transplantation
21. Graft-versus-host disease. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
22. Equivalence of 2 effective graft versus host disease prophylaxis regimens: Results of a prospective blinded randomized trial
23. Management of graft-versus-host disease
24. Early treatment of acute graft versus host disease with high or low dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation
25. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin
26. Graft versus host disease. Pre-emptive therapy of acute graft-versus-host disease: A pilot study with antithymocyte globulin (ATG)
27. Muromonab CD3. A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection
28. OKT-3 for steroid-resistant acute GvHD: A three center experience
29. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host-disease
30. Treatment of steroid refractory acute and chronic graft-versus host disease with daclizumab
31. Tumor necrosis factor/cachetin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
32. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation
33. Treatment of severe refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody
34. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent
35. An old drug for a new disease: Pentostatin (Nipent) in acute graft versus host disease
36. Chronic graft-versus-host disease: Clinical manifestation and therapy
37. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma
38. Chronic graft-versus-host disease: Is there an alternative to the conventional treatment
39. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease
40. Thalidomide for treatment of patients with chronic graft versus host disease
41. Thalidomide for the treatment of chronic graft-versus-host disease
42. Extracorporeal photo chemotherapy in the treatment of severe graft-versus-host disease (GVHD)
43. Extracorporeal photo chemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study
44. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients
45. Drug therapy for acute graft-versus-host disease prophylaxis